Skip to main content

CORRECTION article

Front. Immunol., 21 February 2020
Sec. Cancer Immunity and Immunotherapy
Volume 11 - 2020 | https://doi.org/10.3389/fimmu.2020.00277

RETRACTED: Corrigendum: Natural Killer Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Cancer Progression by Targeting IL-26

A retraction of this article was approved in:

  1. Retraction: Corrigendum: Natural killer cell-derived exosomal miR-3607-3p inhibits pancreatic cancer progression by targeting IL-26

    1. Read retraction
\nHongwei Sun&#x;Hongwei Sun1†Keqing Shi&#x;Keqing Shi2†Kai Qi&#x;Kai Qi3†Hongru KongHongru Kong1Jie ZhangJie Zhang1Shengjie DaiShengjie Dai1Wen YeWen Ye1Tuo DengTuo Deng1Qiye He,Qiye He4,5Mengtao Zhou Mengtao Zhou6*
  • 1Department of Hepatobiliary Surgery, Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of ZheJiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
  • 2Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of ZheJiang Province, Center of Precision Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
  • 3Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China
  • 4Singlera Genomics Inc., San Diego, CA, United States
  • 5Singlera Genomics (Shanghai) Ltd., Shanghai, China
  • 6Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of ZheJiang Province, Precision Medical Center Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

This article has been retracted. Please follow the link to the full retraction notice for details.

Citation: Sun H, Shi K, Qi K, Kong H, Zhang J, Dai S, Ye W, Deng T, He Q and Zhou M (2020) Corrigendum: Natural Killer Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Cancer Progression by Targeting IL-26. Front. Immunol. 11:277. doi: 10.3389/fimmu.2020.00277

Received: 01 January 2020; Accepted: 04 February 2020;
Published: 21 February 2020; Retracted: 19 August 2024.

Edited and reviewed by: Katy Rezvani, University of Texas MD Anderson Cancer Center, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.